Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-bone versus intravenous haploidentical hematopoietic stem cell transplantation for hematologic malignancies
ChiCTR-IPR-15005794Phase 3Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jan 1990
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of haploidentical hematopoietic stem cells and bone marrow mononuclear cells in hematopoietic malignancies, myelodysplastic syndrome (MDS) and leukemia (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Overall survival time and Disease-free survival time. Planned start Jan 1990; status: not yet recruiting.
02
Drugs
haploidentical hematopoietic stem cellsbone marrow mononuclear cells
03
Conditions
hematopoietic malignanciesmyelodysplastic syndrome (MDS)leukemia
Beyond the preview
Go deeper on ChiCTR-IPR-15005794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005794.